Analyzing Derma Sciences (DSCI) & Cynosure (CYNO)
Derma Sciences (NASDAQ: DSCI) and Cynosure (NASDAQ:CYNO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitabiliy, analyst recommendations, risk, institutional ownership and dividends.
Insider and Institutional Ownership
58.9% of Derma Sciences shares are owned by institutional investors. 9.9% of Derma Sciences shares are owned by company insiders. Comparatively, 2.9% of Cynosure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Derma Sciences and Cynosure’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Derma Sciences has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Cynosure has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.
Valuation and Earnings
This table compares Derma Sciences and Cynosure’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
Derma Sciences is trading at a lower price-to-earnings ratio than Cynosure, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Derma Sciences and Cynosure, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cynosure has a consensus price target of $58.57, suggesting a potential downside of 11.22%. Given Cynosure’s stronger consensus rating and higher probable upside, analysts plainly believe Cynosure is more favorable than Derma Sciences.
Cynosure beats Derma Sciences on 8 of the 10 factors compared between the two stocks.
Derma Sciences Company Profile
Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.
Cynosure Company Profile
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.